Number Needed to Treat Estimates Incorporating Effects Over the Entire Range of Clinical Outcomes: Novel Derivation Method and Application to Thrombolytic Therapy for Acute Stroke
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Number needed to treat (NNT) is a useful measure of a treatment's clinical benefit or harm. However, NNT estimates for treatments for neurologic conditions have previously been generated only for dichotomized functional outcomes, which may underestimate clinically relevant treatment effects. OBJECTIVES: To develop a method for estimating NNTs for nonbinary outcomes from parallel design clinical trials and to illustrate its application to outcomes of fibrinolytic stroke therapy across the full range of the modified Rankin Scale (mRS) of disability. METHODS: Expert generation of joint distribution outcome tables in a model population affords a novel means to derive NNTs for nonbinary end points. Using mRS distributions from the National Institute of Neurological Disorders and Stroke-Tissue Plasminogen Activator trials, 10 neurologist and emergency physician acute stroke care experts independently specified the joint distribution of outcomes in model samples of 100 patients assigned to placebo and active therapy. RESULTS: The average estimated NNT for 1 additional patient to have a better outcome by 1 or more grades on the mRS as a result of treatment was 3.1 (95% confidence interval, 2.6-3.6). The estimated number needed to harm was 30.1 (95% confidence interval, 25.1-36.0). Expert estimates were robust across alternative stratifications of the mRS, with the NNT for benefit on 6- and 5-rank versions of 3.3 and 3.7 and the number needed to harm of 56.6 and 100.0, respectively. CONCLUSIONS: Expert generation of joint distribution outcome tables enables NNT estimation across a full spectrum of nonbinary outcomes. For every 100 patients with acute stroke treated with tissue plasminogen activator, approximately 32 have a better final outcome and 3 have a worse final outcome as a result of treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NNTs are smaller with ordinal versus fixed dichotomous approaches, as seen for alteplase in which an NNT of approximately 3 to 4 was present when analyzed using all 7 levels of the mRS versus approximately 8 when assessed for mRS 2 to 6 in a fixed dichotomous analysis.”
From Statistical Analysis of the Primary Outcome in Acute Stroke Trials (2012) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue Plasminogen Activator for Acute Ischemic Stroke
(1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332401 · Cited by 11,654
The number needed to treat: a clinically useful measure of treatment effect
Cook, R. J., & Sackett, D. L. (1995) · BMJ · doi:10.1136/bmj.310.6977.452 · Cited by 1,885 · cited 2×
“N UMBER NEEDED TO TREAT (NNT) is a widely accepted, statistically valid, and clinically useful measure of treatment effect.(1,2) However, methods for deriving NNT estimates were initially described only for binary outcomes.”
BackgroundMethodDefective membrane repair in dysferlin-deficient muscular dystrophy
Bansal, D., Miyake, K., Vogel, S. S., Groh, S., Chen, C.-C., Williamson, R., McNeil, P. L., & Campbell, K. P. (2003) · Nature · doi:10.1038/nature01573 · Cited by 1,022
Interpreting treatment effects in randomised trials
Guyatt, G. H., Juniper, E. F., Walter, S. D., Griffith, L. E., & Goldstein, R. S. (1998) · BMJ · doi:10.1136/bmj.316.7132.690 · Cited by 516 · cited 1×
“Methods to calculate exact NNTs for ordinal or continuous end points have recently been developed.(3,5) However, a key variable in the required formulas is the within-patient correlation— the degree to which the rank order of patient outcomes is similar under control vs active therapy.”
BackgroundDuncan, P. W., Jorgensen, H. S., & Wade, D. T. (2000) · Stroke · doi:10.1161/01.str.31.6.1429 · Cited by 484
Dysferlin is a Plasma Membrane Protein and is Expressed Early in Human Development
Anderson, L. V. B., Davison, K., Moss, J. A., Young, C., Cullen, M. J., Walsh, J., Johnson, M. A., Bashir, R., Britton, S., Keers, S., et al. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.5.855 · Cited by 302
Tissue Plasminogen Activator for Acute Ischemic Stroke
(1996) · New England Journal of Medicine · doi:10.1056/nejm199605233342114 · Cited by 300
The sarcolemmal proteins dysferlin and caveolin-3 interact in skeletal muscle
Matsuda, C. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.17.1761 · Cited by 254
McAlister, F. A., Straus, S. E., Guyatt, G. H., Haynes, R. B., & for the Evidence-Based Medicine Working Group (2000) · JAMA · doi:10.1001/jama.283.21.2829 · Cited by 231
Dystrophin in skeletal muscle I. Western blot analysis using a monoclonal antibody
Nicholson, L. V. B., Davison, K., Falkous, G., Harwood, C., O'Donnell, E., Slater, C. R., & Harris, J. B. (1989) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(89)90223-2 · Cited by 165
Samsa, G. P., Matchar, D. B., Goldstein, L. B., Bonito, A. J., Duncan, P. W., Lipscomb, J., Enarson, C. E., Witter, D. M., Venus, P., Paul, J. E., et al. (1998) · American Heart Journal · doi:10.1016/s0002-8703(98)70019-5 · Cited by 158 · cited 1×
“In contrast, utility preference studies suggest a minority of individuals consider a severely disabled outcome from stroke as an equal or even worse a result than death.(8,9) Therefore, 2 additional NNT and NNH calculations were performed on the expert-specified joint outcome distribution tables: (1) a 6-rank analysis…”
Heterogeneity of dystrophin expression in patients with Duchenne and Becker muscular dystrophy
Nicholson, L. V. B., Johnson, M. A., Gardner‐Medwin, D., Bhattacharya, S. S., & Harris, J. B. (1990) · Acta Neuropathologica · doi:10.1007/bf00294640 · Cited by 158
Dysferlin is a surface membrane–associated protein that is absent in Miyoshi myopathy
Matsuda, C., Aoki, M., Hayashi, Y. K., Ho, M. F., Arahata, K., & Brown, R. H. (1999) · Neurology · doi:10.1212/wnl.53.5.1119 · Cited by 141
Stroke Recovery Profile and the Modified Rankin Assessment
Lai, S.-M., & Duncan, P. W. (2001) · Neuroepidemiology · doi:10.1159/000054754 · Cited by 123 · cited 1×
“In contrast, utility preference studies suggest a minority of individuals consider a severely disabled outcome from stroke as an equal or even worse a result than death.(8,9) Therefore, 2 additional NNT and NNH calculations were performed on the expert-specified joint outcome distribution tables: (1) a 6-rank analysis…”
Number needed to treat (NNT): estimation of a measure of clinical benefit
Walter, S. D. (2001) · Statistics in Medicine · doi:10.1002/sim.1173 · Cited by 80 · cited 2×
“Another approach has been to take an observation of within-patient variance available from previous paired or crossover trials in a particular condition and apply it to parallel-group design trials enrolling patients with the same condition.(5) This approach is sound when relevant data are available, but it is rare fo…”
BackgroundMethodCloning of the mouse dysferlin gene and genomic characterization of the SJL-Dysf mutation
Vafiadaki, E., Reis, A., Keers, S. M., Harrison, R., Anderson, L. V. B., Raffelsberger, T., Ivanova, S., Höger, H., Bittner, R. E., Bushby, K. M. D., et al. (2001) · Neuroreport · doi:10.1097/00001756-200103050-00039 · Cited by 71
Brain Hemorrhage After Thrombolysis: Good or Bad?
von Kummer, R. (2002) · Stroke · doi:10.1161/01.str.0000016923.99605.75 · Cited by 52 · cited 1×
“Other patients have a mild transient worsening in their neurologic deficit caused by hemorrhagic transformation, but their final functional outcome is unaffected.(10) Patients who have a mildly worse final functional outcome as a result of hemorrhagic transformation may not be captured by dichotomized analyses of end…”
BackgroundSaito, A., Higuchi, I., Nakagawa, M., Saito, M., Hirata, K., Suehara, M., Yoshida, Y., Takahashi, T., Aoki, M., & Osame, M. (2002) · Acta Neuropathologica · doi:10.1007/s00401-002-0593-x · Cited by 25
Cited by
Wahlgren, N., Ahmed, N., Dávalos, A., Ford, G. A., Grond, M., Hacke, W., Hennerici, M. G., Kaste, M., Kuelkens, S., Larrue, V., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60149-4 · Cited by 2,379
Banks, J. L., & Marotta, C. A. (2007) · Stroke · doi:10.1161/01.str.0000258355.23810.c6 · Cited by 2,253
The Impact of Recanalization on Ischemic Stroke Outcome: A Meta-Analysis
Rha, J.-H., & Saver, J. L. (2007) · Stroke · doi:10.1161/01.str.0000258112.14918.24 · Cited by 1,452
Self-citationThrombolysis for acute ischaemic stroke
Wardlaw, J. M., Murray, V., Berge, E., & del Zoppo, G. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000213.pub3 · Cited by 1,370
Clinical interpretation and use of stroke scales
Kasner, S. E. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70495-1 · Cited by 934
Metadata
- Authors
- Saver, J. L.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2004-07-01
- Volume
- 61
- Issue
- 7
- Pages
- 1066-70
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W1972257422
- Cited by
- 185
- References
- 18
- FWCI
- 12.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.